T

    TuHURA Biosciences Inc (HURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.13
    +0.02 (+0.95%)

    Market Cap: $135.74M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    29%(8/28)
    Avg Surprise
    -324.08%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.14 - $-0.12
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.13+0.0%
    60d ago$-0.13+0.0%
    30d ago$-0.13+0.0%
    7d ago$0.00+100.0%
    Current$-0.13
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.14
    Range$-0.16 - $-0.12
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.14---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 13
    		$-0.14$-0.15+6.67%Beat+33.3%
    Mar 26
    Reported May 15
    		$-0.13$-0.11-18.18%Miss+13.3%
    Dec 25
    Reported Mar 31
    		$-0.16$-0.12-35.92%Miss-16.5%
    Sep 25
    Reported Nov 14
    		$-0.14$-0.15+6.67%Beat+95.3%
    Jun 25
    Reported Aug 14
    		$-0.21$-0.13-61.54%Miss+86.7%
    Mar 25
    Reported May 15
    		$-0.15$-0.13-15.38%Miss+98.2%
    Dec 24
    Reported Feb 26
    		$-0.14N/A+76.67%Beat+99.8%
    Sep 24
    Reported Nov 14
    		$-3.00$-0.09-3232.56%Miss+95.6%
    Mar 24
    Reported May 14
    		$-1.58N/AN/ABeat+18.5%
    Dec 23
    Reported Feb 15
    		$-8.27N/AN/ABeat-293.9%
    Sep 23
    Reported Nov 14
    		$-63.91N/AN/ABeat-1726.0%
    Jun 23
    Reported Sep 19
    		$-68.25$-36.92-84.86%Miss-170525.0%
    Mar 23
    Reported Jun 29
    		$-1.94$-0.19-921.05%Miss-1663.6%
    Dec 22
    Reported Mar 31
    		$-2.10N/A+73.75%Beat-1650.0%
    Sep 22
    Reported Nov 9
    		$-3.50N/AN/ABeat-1300.0%
    Jun 22
    Reported Sep 27
    		$-0.04$-0.02-100.00%Miss+81.0%
    Mar 22
    Reported Jun 29
    		$-0.11$-0.11-3.09%Miss+52.2%
    Dec 21
    Reported Mar 30
    		$-0.12$-0.17+30.76%Beat+45.5%
    Sep 21
    Reported Nov 15
    		$-0.25$-0.14-74.46%Miss+81.2%
    Jun 21
    Reported Sep 29
    		$-0.21$-0.16-29.23%Miss+38.2%
    Mar 21
    Reported Jun 29
    		$-0.23$-0.18-26.03%Miss-35.3%
    Dec 20
    Reported Mar 30
    		$-0.22$-0.14-54.39%Miss-46.7%
    Sep 20
    Reported Nov 13
    		$-1.33$-0.06-2116.67%Miss-533.3%
    Jun 20
    Reported Sep 21
    		$-0.34$-0.11-209.09%Miss+59.0%
    Mar 20
    Reported Jun 29
    		$-0.17$-0.11-54.55%Miss+74.6%
    Dec 19
    Reported Mar 30
    		$-0.15$-0.15+0.00%Beat+81.3%
    Sep 19
    Reported Nov 14
    		$-0.21$-0.18-16.67%Miss+76.7%
    Jun 19
    Reported Sep 10
    		$-0.83$-0.33-151.52%Miss-654.5%
    Mar 19
    Reported Jun 29
    		$-0.67$-0.70+4.29%Beat+100.0%
    Dec 18
    Reported Mar 30
    		$-0.80$-0.07-1042.86%Miss+100.0%
    Sep 18
    Reported Nov 14
    		$-0.90$-0.08-1025.00%Miss+100.0%
    Jun 18
    Reported Sep 24
    		$-0.11$-0.11+0.00%Beat+100.0%
    Mar 18
    Reported Jun 29
    		$-2283.79N/AN/ABeat+27.3%
    Dec 17
    Reported Mar 30
    		$-2494.50N/AN/ABeat-9.9%
    Sep 17
    Reported Nov 14
    		$-3098.93N/AN/ABeat+23.0%
    Jun 17
    Reported Sep 28
    		$-3500.00N/AN/ABeat-
    Mar 17
    Reported Jun 29
    		$-3142.35N/AN/ABeat-
    Dec 16
    Reported Mar 30
    		$-2269.71N/AN/ABeat-
    Sep 16
    Reported Nov 14
    		$-4022.18N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-3.72EV/EBITDAN/A
    Price/FCF-4.56xFCF Yield-21.95%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-161.40%ROIC-127.78%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio0.18xQuick Ratio0.18x
    Trading Statistics
    BetaN/AAvg Volume263.52K
    52-Week High$3.4352-Week Low$0.41

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.13
    SMA 20$2.18
    SMA 50$2.25
    SMA 200$1.82
    EMA 10$2.14
    EMA 20$2.17
    EMA 50$2.21
    EMA 200$2.12

    MACD

    Line: -0.03Signal: -0.02Hist: -0.01

    ADX

    ADX: 15.0+DI: 15.4-DI: 18.8

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down76.0
    PSAR$2.51

    Bollinger Bands

    Upper Band$2.41
    Lower Band$1.95
    %B Position2102%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    47.4

    Momentum Oscillators

    Stoch %K22.6
    Stoch %D21.3
    Williams %R-76.3
    ROC (10d)-6.6%
    Momentum-0.15
    CCI (20d)-32.8
    MFI (14d)58.4

    Volatility Measures

    ATR (14d)$0.16(7.4%)
    StdDev (20d)0.11
    Hist Vol76.7%(High)

    Volume Flow

    VWAP$2.15
    OBV-11.4M
    AD Line172.9K
    CMF (20d)-0.317

    Volume Metrics

    Avg Vol (20d)266.3K
    Vol Ratio0.9x
    VWMA (20d)$2.22

    Pivot Points

    R3$2.27
    R2$2.21
    R1$2.16
    Pivot Point$2.10
    S1$2.05
    S2$1.99
    S3$1.94

    Advanced Oscillators

    TSI-5.46
    Ultimate Osc39.1
    KST-26.42

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0N/A$0$0$0N/AN/A
    Cost of RevenueN/A$23,472N/A$21,000N/A$14,058$17,635$29,000$17,000$34,307$15,000$15,000
    Gross ProfitN/A$-23,472N/A$-21,000N/A$-14,058$-17,635$-29,000$-17,000$-34,307$-15,000$-15,000
    Operating Expenses$8.76M$7.51M$8.17M$6.73M$9.88M$7.02M$5.68M$3.70M$2.37M$4.61M$1.00M$2.95M
    R&D$6.62M$5.23M$6.06M$4.97M$4.93M$4.58M$3.98M$2.95M$101,000$3.59M$111,000$1.86M
    SG&A$2.14M$2.30M$1.56M$1.76M$1.05M$2.02M$0$1.96M$795,660$1.02M$0$0
    Operating Income$-8,763,284$-7,529,899$-8,173,357$-6,729,603$-9,875,956$-7,017,023$-5,694,786$-3,730,228$-2,385,000$-4,605,754$-1,019,000$-2,962,000
    Interest Income$0$21,275$609$6,060$29,466$100,098$0$0$58,040$6,642$0$0
    Interest Expense$467,634$27,974$608,751$16,532$0$0$522,835$2.00M$1.36M$255,122$3,999$0
    Income Before Tax$-9,223,298$-7,536,598$-6,761,316$-7,102,455$-9,523,835$-6,664,371$-5,995,811$-5,579,118$-2,324,000$-4,842,142$-1,022,999$-2,962,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,223,298$-7,536,598$-6,769,672$-7,102,455$-9,523,835$-6,664,371$-5,995,811$-5,579,118$-2,324,000$-4,842,142$-1,022,999$-2,962,000
    EBITDA$-8,727,560$-7,485,152$-6,130,021$-7,064,631$-9,510,464$-6,650,313$-5,455,341$-3,547,232$-2,307,000$-4,552,713$-1,008,000$-2,947,000
    EBIT$-8,755,664$-7,508,624$-6,152,565$-7,085,923$-9,523,835$-6,664,371$-5,472,976$-3,576,232$-2,324,000$-4,587,020$-1,023,000$-2,962,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HURA

    News

    TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting

    TuHURA Biosciences (NASDAQ: HURA) stockholders approved the issuance of 1,878,287 shares to Parkview Holdings One LLC as part of a $50 million revolving credit facility, addressing the company's liquidity challenges. Shareholders also elected six directors to the board and ratified Cherry Bekaert LLP as the independent accounting firm for the fiscal year 2026. Despite recent stock declines, the company's year-to-date return is 185%, and it recently filed an Investigational New Drug (IND) application for TBS-2025 VISTA inhibiting antibody to treat acute myeloid leukemia.

    Investing.com•8/19/26•
    Somewhat-Bearish

    Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com

    This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 19, 2026. The Form 8K filing is a common regulatory requirement for companies to disclose significant events to shareholders and the SEC. Further details about the content of the Form 8K are not provided in this brief announcement.

    Investing.com Canada•8/19/26•
    Neutral

    TuHURA Biosciences | 8-K: Current report

    This article is a current report (8-K) filed by TuHURA Biosciences. The content of the report is not provided in this snippet.

    Moomoo•8/19/26•
    Neutral

    TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting

    TuHURA Biosciences (NASDAQ:HURA) stockholders approved the issuance of 1,878,287 shares of common stock to Parkview Holdings One LLC as part of a $50 million revolving credit facility, addressing the company's liquidity pressures. Shareholders also elected six directors and ratified Cherry Bekaert LLP as the independent accounting firm for 2026. The company recently filed an IND application for its TBS-2025 VISTA inhibiting antibody and received a Market Outperform rating from Citizens.

    Investing.com•8/19/26•
    Neutral

    HURA: All proposals passed, including director elections and share issuance, with no stockholder questions

    TuHURA Biosciences, Inc. (HURA) held its AGM 2026 where all proposals were passed, including director elections, share issuance, executive compensation, and auditor ratification. Stockholders supported the board's recommendation for a three-year frequency for compensation votes, and no questions were raised during the meeting. This information is based on an AI-generated summary of the AGM 2026 audio transcript.

    TradingView•8/18/26•
    Bullish

    Frequently Asked Questions About HURA

    Does HURA pay dividends?
    TuHURA Biosciences Inc (HURA) does not currently pay a regular dividend.
    What is HURA's market cap?
    TuHURA Biosciences Inc (HURA) has a market capitalization of $135.74M with a current stock price of $2.13.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In